To learn more about the user friendly high-throughput solutions from BÜHLMANN visit our website for the EUROMEDLAB 2022 highlights and join us in Munich.
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
Quantum Blue® Infliximab and Quantum Blue® Adalimumab offer quantification of infliximab and adalimumab originator drugs, as well as their biosimilars, allowing for identification of patients with suboptimal drug levels as part of their therapeutic drug monitoring.
The guidelines on the diagnosis and treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were revised by a taskforce recently. They advise anti-MAG antibody testing by means of BÜHLMANN anti-MAG Autoantibodies ELISA in all patients with an IgM paraprotein fulfilling CIDP diagnostic criteria.
At the European Crohn’s and Colitis Organization (ECCO) 2021 congress Therapeutic Drug Monitoring (TDM) as well as remote monitoring were key topics with the ongoing pandemic forcing new ways of patient care. Of the presented abstracts, several stand out as they are using IBDoc® or BÜHLMANN’s Quantum Blue® TDM portfolio.
Social Links